Drug Detail:Tecovirimat (oral/injection) (Tecovirimat (oral/injection) [ tek-oh-vir-i-mat ])
Drug Class: Miscellaneous antivirals
Tecovirimat Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the use of tecovirimat during breastfeeding. Because of relatively high protein binding and low oral absorption, exposure of the breastfed infant is likely to be low. Additionally, tecovirimat is approved for use in pediatric patients weighing as little as 3 kg. Amounts in breastmilk are unlikely to adversely affect the breastfed infant. However, individuals with smallpox are recommended not to breastfeed their infant because of the risk of passing variola virus to the infant through direct contact. This precaution probably applies to monkeypox, also. Providing pumped milk to the infant may be possible if no lesions are near the breast and adequate precautions are taken with respect to cleaning hands, breasts, breast pumps and any other apparatuses used to provide milk to the infant.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Tecovirimat
CAS Registry Number
869572-92-9
Drug Class
Breast Feeding
Lactation
Milk, Human
Anti-Infective Agents
Antiviral Agents
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification